Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Daniela Fraboni, PhD, Emanuele Ammatuna, MD, Maria Irno Consalvo, PhD, Paola Panetta, PhD, Licia Ottaviani, MD, Sabrina Faccia, MD, Manuela Rizzo, MD, Massimiliano Postorino, MD, Maria Cantonetti, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2007) 110 (11): 3498.

https://doi.org/10.1182/blood.V110.11.3498.3498

Published: 2007

Journal Articles

Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.

Francesco Buccisano, MD, Luca Maurillo, MD, Valter Gattei, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Fraboni Fraboni, Phd, Paola Panetta, Phd, Maria Irno Consalvo, Phd, Selenia Campagna, MD, Laura Giannì, MD, Licia Ottaviani, MD, Massimiliano Postorino, MD, Paolo De Fabritiis, MD, William Arcese, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2006) 108 (11): 610.

https://doi.org/10.1182/blood.V108.11.610.610

Published: 2006

Journal Articles

Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML).

Francesco Buccisano, MD, Luca Maurillo, MD, Valter Gattei, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Paola Panetta, Phd, Daniela Fraboni, Phd, Maria Irno Consalvo, Phd, Licia Ottaviani, MD, Daniela Renzi, MD, Sabrina Faccia, MD, Chiara Sarlo, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2006) 108 (11): 2299.

https://doi.org/10.1182/blood.V108.11.2299.2299

Published: 2006

Journal Articles

Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM).

Luca Maurillo, MD, Francesco Buccisano, MD, Benedetta Neri, MD, Carla Mazzone, MD, Giovanni Del Poeta, MD, Licia Ottaviani, MD, Pasquale Niscola, MD, Ilaria Del Principe, MD, Anna Tamburini, MD, Maria Irno Consalvo, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2005) 106 (11): 2361.

https://doi.org/10.1182/blood.V106.11.2361.2361

Published: 2005

Journal Articles

The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Anna Tamburini, MD, Maria Christina Cox, MD, Maria Ilaria Del Principe, MD, Maria Irno Consalvo, PhD, Carla Mazzone, MD, Benedetta Neri, MD, Licia Ottaviani, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2004) 104 (11): 399.

https://doi.org/10.1182/blood.V104.11.399.399

Published: 2004

NARROW

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.

Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML).

Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM).

The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.

Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML).

Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM).

The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only